First human test of promising new obesity drug
NCT ID NCT04478708
Summary
This early-stage study tested the safety and side effects of an experimental drug called AMG 133 (maridebart cafraglutide) in adults with obesity. The main goal was to see how the body processes the drug and what side effects occur when given as single or multiple doses. Researchers enrolled 110 otherwise healthy adults with a body mass index between 30 and 40 to participate.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Anaheim Clinical Trials
Anaheim, California, 92801, United States
-
Clinical Pharmacology of Miami, LLC
Miami, Florida, 33014, United States
-
Orange County Research Center
Tustin, California, 92780, United States
Conditions
Explore the condition pages connected to this study.